Biograil closes €20m round to prepare oral drug delivery device for trials
Verve Ventures, Megatrend Invest and HTGF Opportunity back development of Biograil’s BIONDD platform.
Biograil has closed a €20 million financing round to advance preparations for Phase 1 clinical testing of its BIONDD oral drug delivery device. Verve Ventures and Megatrend Invest backed the Danish company, with HTGF participating through its HTGF Opportunity growth fund.
The capital will support non-clinical studies under Good Laboratory Practice and the establishment of manufacturing processes under Good Manufacturing Practice. These milestones are intended to prepare the platform for clinical development ahead of a larger financing planned for 2027.
BIONDD is designed to carry medicines inside a swallowable capsule and deliver them through the stomach wall. Biograil is developing the injection-moulded device for therapeutics, including biologics, that would otherwise require injection. The company remains at the preclinical stage.
Use of funds
Prepare BIONDD for Phase 1 clinical testing
Conduct non-clinical GLP studies
Establish GMP manufacturing processes